Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process

JAMA. 2020 Jun 16;323(23):2365-2366. doi: 10.1001/jama.2020.8863.

Authors

Michael G Ison¹, Cameron Wolfe², Helen W Boucher³

Affiliations

¹ Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina.
³ Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts.

PMID: 32407438
DOI: 10.1001/jama.2020.8863

No abstract available

MeSH terms

Adenosine Monophosphate / analogs & derivatives*
Adenosine Monophosphate / supply & distribution
Adenosine Monophosphate / therapeutic use
Alanine / analogs & derivatives*
Alanine / supply & distribution
Alanine / therapeutic use
Antiviral Agents / supply & distribution*
Antiviral Agents / therapeutic use
Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Drug Approval
Emergencies
Humans
Pandemics
Pneumonia, Viral / drug therapy*
SARS-CoV-2
United States

Substances

Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine